Stockscreener 앱 받기
216.49
2.14%
-4.74
시간 외 거래:
217.20
0.71
+0.33%
전일 마감가:
$221.23
열려 있는:
$221.37
하루 거래량:
9.56M
Relative Volume:
1.50
시가총액:
$382.49B
수익:
$62.82B
순이익/손실:
$3.60B
주가수익비율:
106.78
EPS:
2.0274
순현금흐름:
$19.98B
1주 성능:
-3.68%
1개월 성능:
+3.38%
6개월 성능:
-2.84%
1년 성능:
+16.71%
1일 변동 폭
$215.37
$222.35
1주일 범위
$215.37
$228.40
52주 변동 폭
$181.73
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Approaching $11 Billion Deal for Apogee Therapeutics, Report Says - Bloomberg.com
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports - Yahoo! Finance Canada
AbbVie approaching $11B deal for Apogee Therapeutics: report - Crain's Chicago Business
AbbVie, Apogee Therapeutics said to near $11B deal - Breakingthenews.net
AbbVie closes in on nearly $11bn deal for biotech Apogee Therapeutics - Financial Times
AbbVie: Immunology Cash Flow Funds Oncology Expansion (NYSE:ABBV) - Seeking Alpha
Why Is AbbVie Attracting Attention (NYSE:ABBV) - Kalkine Media
AbbVie To Go Ex-Dividend On July 15th, 2026 With 1.73 USD Dividend Per Share - Moomoo
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie declares quarterly dividend of $1.73 per share - Investing.com
AbbVie declares quarterly dividend of $1.73 per share By Investing.com - Investing.com Canada
AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable Aug. 14 to Holders of Record July 15 - marketscreener.com
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 14, 2026 - marketscreener.com
AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress - Yahoo Finance
OSTERWEIS CAPITAL MANAGEMENT INC's AbbVie Inc(ABBV) Holding History - GuruFocus
HHS Urges DC Court To Toss AbbVie 340B Audit Challenge - Law360
The Answer Is Inside You: The Complexities of Autoimmune Research - AbbVie
AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination - Yahoo Finance
HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients - Bloomberg Law News
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie Inc (ABBV) Stock Price, Trades & News - GuruFocus
Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed - Investing.com
VANGUARD WELLINGTON FUND's AbbVie Inc(ABBV) Holding History - GuruFocus
NYLIM VP Epoch U.S. Equity Yield Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie: Maintaining My Strong Buy Rating After Label Expansion (NYSE:ABBV) - Seeking Alpha
This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie - Yahoo Finance
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Trade Ideas — BCBA:ABBV.CI - TradingView
AbbVie Stock Will Hit $300 on This Date - 24/7 Wall St.
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance - Investing News Network
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie Stock in 2026: Skyrizi and Rinvoq Drive 12% Revenue Growth as Margins Begin to Inflect - TIKR.com
S&P upgrades AbbVie outlook on immunology drug growth By Investing.com - Investing.com Australia
S&P upgrades AbbVie outlook on immunology drug growth - Investing.com
AbbVie, Chevron, and Enterprise Products' Dividend Prospects - Intellectia AI
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - GlobeNewswire Inc.
AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73 - Yahoo Finance
AbbVie (ABBV) Receives a Hold from Citi - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV) - The Globe and Mail
AbbVie (ABBV) Rises Higher Than Market: Key Facts - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients - Benzinga
AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy (NYSE:ABBV) - Seeking Alpha
AbbVie presents Phase III venetoclax data in first-line CLL - The Pharma Letter
AbbVie reports nine-year CLL14 trial data for Venclexta at EHA 2026 - grafa.com
6,889 Shares in AbbVie Inc. $ABBV Bought by Winning Points Advisors LLC - MarketBeat
Woodley Farra Manion Portfolio Management Inc. Has $5.30 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. - Yahoo Finance
Logan Capital Management Inc. Sells 8,592 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results - Investing News Network
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
자본화:
|
볼륨(24시간):